OrbiMed Advisors LLC's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jun 17, 2026
- Accession no.
- 0000947871-26-000637
- Filed
- Jun 17, 2026, 7:45 PM ET
- Trade date
- Jun 15, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $12.7M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | 10% Owner |
| OrbiMed Capital GP VII LLCCIK 0001760648 | 10% Owner |
| OrbiMed Genesis GP LLCCIK 0001808744 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Common Stock | SSaleDisposed | −9,086 | $45.02 | −$409,051.72 | 245,728 | Indirect | |
| Jun 15, 2026 | Common Stock | SSaleDisposed | −272,322 | $45.02 | −$12,259,936.44 | 7,388,902 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.